CD163 and pancreatic neoplasm: EpCAM+ cancer cells (PD-L1− or TIM-3−), CD8+ T cells with either PD-1+ or TIM-3+, and CD14+CD68+CD163+TIM-3+ macrophages increased in the MPE of a patient with progressive pancreatic cancer (Figure 1).